Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomized controlled trial - Ridker, P M; MacFadyen, J G; Everett, B M; CANTOS Trial Group (Lancet, 2018)
et al.